AKT1 and hepatocellular carcinoma: Accordingly, the treatment of HCC cell lines with a DNA-demethylating agent (5-aza dC) and an MK2 inhibitor restores the TTP expression and activity in HCC cells, thereby decreasing the expression of TTP targets (e.g., c-MYC, IER3 or AKT) and inducing cell death [73].